标题
Treatment of rheumatic adverse events of cancer immunotherapy
作者
关键词
-
出版物
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume -, Issue -, Pages 101805
出版商
Elsevier BV
发表日期
2022-12-18
DOI
10.1016/j.berh.2022.101805
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis
- (2022) Koichi Takeda et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
- (2022) Yared Hailemichael et al. CANCER CELL
- IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy
- (2022) Julie Delyon et al. CANCER CELL
- Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy
- (2022) Vincent T Ma et al. Immunotherapy
- Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature
- (2022) Yuki Nakagomi et al. Frontiers in Pharmacology
- Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study
- (2022) Léo Plaçais et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune Checkpoint Inhibitor–Associated Myositis
- (2022) Didem Saygin et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
- (2022) Masatoshi Kudo Hepatobiliary Surgery and Nutrition
- Effect of immune checkpoint inhibitor-induced rheumatic and musculoskeletal disorders on overall survival
- (2021) Leslie Adda et al. JOINT BONE SPINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases
- (2021) Chunlan Wu et al. Immunotherapy
- Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer
- (2021) Leah L. Thompson et al. JAMA Dermatology
- Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors
- (2021) Nilasha Ghosh et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.
- (2021) Inderjit Mehmi et al. JOURNAL OF CLINICAL ONCOLOGY
- Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
- (2021) Pankti Reid et al. Journal for ImmunoTherapy of Cancer
- Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities
- (2021) Samia Hajem et al. EUROPEAN JOURNAL OF CANCER
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
- (2021) Jia Luo et al. Journal of Thoracic Oncology
- Infectious complications of immune checkpoint inhibitors in solid organ malignancies
- (2021) Justine Abella Ross et al. Cancer Medicine
- Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis?An analysis of the WHO’s adverse drug reactions database
- (2020) Thủy Nguyễn et al. ANNALS OF THE RHEUMATIC DISEASES
- Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry
- (2020) Rik J. Verheijden et al. CLINICAL CANCER RESEARCH
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2020) Fausto Petrelli et al. Cancers
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
- (2020) Marie Kostine et al. ANNALS OF THE RHEUMATIC DISEASES
- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
- (2020) Xiaoxiang Zhou et al. BMC Medicine
- Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature
- (2020) Olga Nigro et al. Immunotherapy
- Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside
- (2020) Antonio G. Solimando et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Checkpoint Inhibitor–Associated Arthritis
- (2020) Nilasha Ghosh et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort
- (2020) Janet Roberts et al. AUTOIMMUNITY REVIEWS
- Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
- (2020) Yves Allenbach et al. AUTOIMMUNITY REVIEWS
- Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
- (2020) Anne Montfort et al. CLINICAL CANCER RESEARCH
- Infectious complications in patients treated with immune checkpoint inhibitors
- (2020) Jean-Denis Karam et al. EUROPEAN JOURNAL OF CANCER
- Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors
- (2020) Jeffrey Aldrich et al. Arthritis & Rheumatology
- A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
- (2019) Patrick Arnaud-Coffin et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
- (2019) Alessio Cortellini et al. ONCOLOGIST
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- (2019) Celeste Lebbé et al. JOURNAL OF CLINICAL ONCOLOGY
- Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
- (2019) Blake M. Warner et al. ONCOLOGIST
- Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
- (2019) Emanuel Raschi et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
- (2019) Jeroen M.k. de Filette et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
- (2019) Tawnie J Braaten et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
- (2019) Houssein Safa et al. Journal for ImmunoTherapy of Cancer
- Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis
- (2019) Jiang-lin Wang et al. CLINICAL RHEUMATOLOGY
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
- (2018) Laura C. Cappelli et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
- (2018) Yinghong Wang et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Inhibitor–Associated Myositis
- (2018) Céline Anquetil et al. CIRCULATION
- Reporting of immune checkpoint inhibitor-associated myocarditis
- (2018) Sadeer G Al-Kindi et al. LANCET
- Rheumatic immune-related adverse events from cancer immunotherapy
- (2018) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
- (2018) Alvaro Moreira et al. EUROPEAN JOURNAL OF CANCER
- Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy
- (2018) David F. L. Liew et al. International Journal of Rheumatic Diseases
- Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis
- (2018) Laura C Cappelli et al. RHEUMATOLOGY
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
- (2017) D. Makarious et al. EUROPEAN JOURNAL OF CANCER
- Trial of Tocilizumab in Giant-Cell Arteritis
- (2017) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
- (2017) Jarushka Naidoo et al. ONCOLOGIST
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- (2017) Laura C. Cappelli et al. ARTHRITIS CARE & RESEARCH
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
- (2016) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers
- (2016) Karin Hellgren et al. ANNALS OF THE RHEUMATIC DISEASES
- The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
- (2016) Maria Del Castillo et al. CLINICAL INFECTIOUS DISEASES
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer
- (2016) Frank I. Scott et al. JAMA Dermatology
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
- (2013) P. Raaschou et al. BMJ-British Medical Journal
- Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases
- (2012) Kevin Haynes et al. ARTHRITIS AND RHEUMATISM
- Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy
- (2012) Maria A. Lopez-Olivo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interleukin-6 and melanoma
- (2012) Lise Hoejberg et al. MELANOMA RESEARCH
- Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials
- (2011) Andrew E. Thompson et al. ARTHRITIS AND RHEUMATISM
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
- (2010) Johan Askling et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Serum interleukin-6 levels in colorectal cancer patients—a summary of published results
- (2009) Heike Knüpfer et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials
- (2008) T Bongartz et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
- Interleukin-6, Cortisol, and Depressive Symptoms in Ovarian Cancer Patients
- (2008) Susan K. Lutgendorf et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now